Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial
Source: View publication →
In patients undergoing non-cardiac surgery, initiating extended-release metoprolol perioperatively reduced the risk of myocardial infarction but significantly increased the risks of debilitating stroke and overall mortality.
Key Findings
Study Design
Study Limitations
Clinical Significance
The POISE trial fundamentally shifted the paradigm in perioperative cardiovascular care. Before this study, initiating beta-blockade in high-risk patients prior to non-cardiac surgery was heavily endorsed by guidelines as a cardioprotective quality measure. POISE demonstrated that although beta-blockers do reduce perioperative myocardial infarction, abrupt initiation significantly increases the risk of hypotension and bradycardia, directly driving an unacceptable excess in mortality and strokes. Consequently, major guidelines were rewritten to explicitly warn against starting high-dose beta-blockers on the day of surgery, instead recommending continuation of beta-blockers only in patients who are already on them chronically.
Historical Context
During the late 1990s and early 2000s, perioperative beta-blocker administration became a ubiquitous standard of care, primarily driven by smaller positive trials (like Mangano et al.) and the highly influential DECREASE trials by Don Poldermans. These earlier studies suggested immense survival benefits. The POISE trial was launched to definitively validate this practice in a large, rigorous, multicenter cohort. The startling findings of increased death and stroke reversed over a decade of clinical momentum. Years later, the foundational DECREASE trials were found to contain fabricated data, fully vindicating the cautionary results of POISE and highlighting the importance of robust, large-scale RCTs before implementing universal quality metrics.
Guided Discussion
High-yield insights from every perspective
Why might beta-blockade in the perioperative period lead to an increased risk of stroke despite successfully protecting against myocardial infarction?
Key Response
Beta-blockers blunt the sympathetic nervous system's response to surgical stress, pain, and hypovolemia. While this decreases myocardial oxygen demand and prevents ischemic MIs, it can also lead to profound, uncompensated hypotension and bradycardia. In vulnerable patients, this severe systemic hypotension compromises cerebral perfusion, leading to anoxic brain injury or ischemic stroke.
Based on the POISE trial results, how should you manage a patient scheduled for an elective hemicolectomy tomorrow who is currently taking a home dose of metoprolol, compared to a patient with multiple cardiac risk factors who is not currently on a beta-blocker?
Key Response
For the patient already taking metoprolol chronically, the home dose should generally be continued (or converted to an equivalent IV dose if NPO) to prevent beta-blocker withdrawal and rebound tachycardia. For the beta-blocker naive patient, the POISE trial strongly argues against initiating a beta-blocker on the day of surgery due to the significant risk of stroke and mortality.
The POISE trial used a fixed, relatively high dose of extended-release metoprolol succinate (100 mg) starting just hours before surgery. How might the results have differed if a careful titration approach over several weeks was used, and what does the historical context of perioperative trials tell us about this?
Key Response
A fixed, high-dose acute strategy fails to account for individual hemodynamic variability, directly causing the severe hypotension/bradycardia seen in POISE. A careful titration starting weeks in advance might allow for tolerance and dose optimization, potentially preserving the cardiac benefits without the stroke risk. This contrasts with earlier, largely discredited data (like the DECREASE trials) that previously supported aggressive perioperative beta-blockade.
As an attending teaching in the pre-op clinic, how do you use the POISE trial to explain the concept of 'competing risks' and patient-centered outcomes when deciding whether a perioperative intervention is truly beneficial?
Key Response
POISE is a classic example of a severe medical trade-off. For every 1000 patients, metoprolol prevented 15 MIs but caused 8 deaths and 5 debilitating strokes. Teaching this emphasizes that reducing a specific surrogate or organ-specific endpoint (like an asymptomatic perioperative MI) is entirely counterproductive if the intervention worsens the ultimate, definitive patient-centered outcomes (overall survival and neurological independence).
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
How did the choice of the primary composite outcome (cardiovascular death, non-fatal MI, and non-fatal cardiac arrest) in the POISE trial design interact with the secondary safety endpoints, and what is the methodological danger of relying solely on composites?
Key Response
Composite endpoints combine outcomes to increase statistical power. In POISE, the primary composite was significantly reduced, driven almost entirely by a reduction in non-fatal MIs. If evaluated in a vacuum, the intervention appears successful. However, the secondary endpoints revealed an increase in total mortality and stroke. This highlights the methodological danger of composite endpoints: a benign or less-severe component can mask significant harm in more severe, non-composite domains.
The POISE trial investigators elected to use a starting dose of 100 mg of extended-release metoprolol. As a peer reviewer, what are the primary external validity concerns regarding this specific dosing regimen, and how does it threaten the generalizability of the trial's conclusions regarding perioperative beta-blockade as a whole?
Key Response
100 mg of ER metoprolol is a highly aggressive starting dose for a beta-blocker naive patient, especially immediately preceding the massive fluid shifts and bleeding risks of major surgery. Critics argue the trial does not evaluate 'perioperative beta-blockade' per se, but rather evaluates 'inappropriate acute high-dose beta-blockade,' limiting the ability to generalize these harms to a more cautious, low-dose, or titrated approach.
How did the findings of the POISE trial directly influence the ACC/AHA guidelines regarding the perioperative use of beta-blockers, specifically altering the strength of recommendation for initiating these medications on the day of surgery?
Key Response
Prior to POISE, perioperative beta-blockade was widely encouraged to prevent MIs. Following the definitive demonstration of harm (stroke and death) in POISE, the ACC/AHA guidelines were updated to issue a strong Class III (Harm) recommendation against starting beta-blockers on the day of surgery in beta-blocker naive patients (Level of Evidence: B). The guidelines now emphasize that if beta-blockers are to be initiated, it should be done weeks in advance with careful titration, while maintaining a Class I recommendation for continuing them in patients already on chronic therapy.
Clinical Landscape
Noteworthy Related Trials
DIPOM Trial
Tested
Metoprolol 100mg daily
Population
Diabetic patients undergoing major non-cardiac surgery
Comparator
Placebo
Endpoint
Composite of all-cause mortality, acute MI, unstable angina, or heart failure
MaVS Trial
Tested
Metoprolol
Population
Patients undergoing abdominal aortic surgery or infrainguinal arterial reconstruction
Comparator
Placebo
Endpoint
Composite of CV death, MI, unstable angina, heart failure, or stroke at 30 days
POISE-2 Trial
Tested
Low-dose aspirin and/or clonidine
Population
Patients undergoing non-cardiac surgery with or at risk for CV disease
Comparator
Placebo
Endpoint
Composite of death or nonfatal myocardial infarction at 30 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis